A Phase 2 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by COMPASS Pathways. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.
Sponsored by COMPASS Pathways · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 19th largest by enrollment, is the only one that started in 2020, is one of 18 in phase 2, and was the 4th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
Centre Hospitalier St Anne · Sites in France
Ages 18+
Beersheva Mental Health Center · Sites in Israel
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University of Texas at Austin · Sites in United States
Ages 22–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 19 · Phase 3 3
First in 2019; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 30 across the 25 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 25 have an industry lead sponsor. The 10 most frequent:
COMPASS Pathways is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
COMPASS Pathways has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
3 of the studies testing psilocybin in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT06518720Centre for Addiction and Mental HealthTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | 2027-03 |
| NCT07183748Beersheva Mental Health CenterPsilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
A recent open label study of the effects of psilocybin in participants with treatment-resistant depression (TRD) showed rapid significant decrease of depressive symptoms after treatment with psilocybin coupled with psychological support. Over 40% of participants sustained response at 3 months. In this study, the aim is to explore effectiveness of 25 mg of psilocybin as an adjunctive therapy in participants with TRD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Psychiatric Exclusion Criteria:
Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin, including exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current depressive episode.
General Medical Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25 mg COMP360 Psilocybin
Drug: Psilocybin
Open label
Also known as: COMP360
Improvement in Depressive Symptoms
Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to 3 weeks post psilocybin administration. The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.
Time frame: 3 weeks
Incidence of Response
The proportion of participants with a response (defined as a ≥ 50% improvement in Montgomery-Asberg Depression Rating Scale \[MADRS\] total score from Baseline) at Week 3 post psilocybin administration. The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.
Time frame: 3 weeks
Incidence of Remission
The proportion of participants with remission (defined as Montgomery-Asberg Depression Rating Scale \[MADRS\] total score ≤ 10) at Week 3 post psilocybin administration The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.
Time frame: 3 weeks
Improvement in Clinical Global Impression - Severity
Changes from Baseline in Clinical Global Impression-Severity score at Week 3 post psilocybin administration. The minimum and maximum values are 1 and 7 and a higher score means a worse outcome.
Time frame: 3 weeks
First patient first visit: 10 August 2020 Last patient last visit: 13 October 2021
| Milestone | 25 mg COMP360 Psilocybin |
|---|---|
| Started | 19 |
| Completed | 19 |
| Not completed | 0 |
Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to 3 weeks post psilocybin administration. The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.
| units on a scale | 25 mg COMP360 Psilocybin |
|---|---|
| Improvement in Depressive Symptoms | -14.9 ± 11.97 |
The proportion of participants with a response (defined as a ≥ 50% improvement in Montgomery-Asberg Depression Rating Scale \[MADRS\] total score from Baseline) at Week 3 post psilocybin administration. The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.
| Participants | 25 mg COMP360 Psilocybin |
|---|---|
| Incidence of Response | 8 |
The proportion of participants with remission (defined as Montgomery-Asberg Depression Rating Scale \[MADRS\] total score ≤ 10) at Week 3 post psilocybin administration The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.
| Participants | 25 mg COMP360 Psilocybin |
|---|---|
| Incidence of Remission | 8 |
Changes from Baseline in Clinical Global Impression-Severity score at Week 3 post psilocybin administration. The minimum and maximum values are 1 and 7 and a higher score means a worse outcome.
| units on a scale | 25 mg COMP360 Psilocybin |
|---|---|
| Improvement in Clinical Global Impression - Severity | -1.3 ± 1.29 |
Collected over Up to 3 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 25 mg COMP360 Psilocybin | 0/19 (0%) | 0/19 (0%) | 12/19 (63.2%) |
| Event | 25 mg COMP360 Psilocybin |
|---|---|
| HeadacheNervous system disorders | 6/19 |
| Blood Pressure IncreasedInvestigations | 3/19 |
| PalpitationsCardiac disorders | 1/19 |
| VertigoEar and labyrinth disorders | 1/19 |
| DiarrhoeaGastrointestinal disorders | 1/19 |
| Dry MouthGastrointestinal disorders | 1/19 |
| FallInjury, poisoning and procedural complications | 1/19 |
| Skin AbrasionInjury, poisoning and procedural complications | 1/19 |
| DizzinessNervous system disorders | 1/19 |
| DepressionPsychiatric disorders | 1/19 |
| Age, Categorical(Participants) | Psilocybin |
|---|---|
| <=18 years | 4 |
| Between 18 and 65 years | 15 |
| >=65 years | 0 |
| Age, Continuous(years) | Psilocybin |
|---|---|
| Mean | 42.2 ± 10.80 |
| Sex: Female, Male(Participants) | Psilocybin |
|---|---|
| Female | 13 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | Psilocybin |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Psilocybin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | Psilocybin |
|---|---|
| United States | 9 |
| Ireland | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Oct 2021, 14 months.
Results were first posted in Nov 2023, 2 years after primary completion.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Depressive Disorder, Treatment-Resistant →
COMPASS Pathways